Liver disease remains a major challenge for accurate differential diagnosis. Several different types of lesions are commonly found in the liver. Liver is a prime focus for metastatic extension of numerous malignancies. Often, both benign and malignant lesions co-exist. It is critical for optimal treatment planning and follow-up to clearly differentiate each lesion type. Despite advances in technology, a large lumber of lesions are missed or incorrectly diagnosed. There remains a clear need for improved imaging 3gents that maximize the capabilities of rapidly evolving diagnostic technologies. Diagnosis of liver pathology using magnetic resonance imaging (MRI) continues to be limited by the lack of a liver-specific imaging agent with a well-defined vascular phase. Eagle Vision Pharmaceutical Corp. is developing EVP-ABD, a manganese-based MRI agent, to address unmet needs for improved differential diagnosis of liver and abdominal diseases. Studies demonstrated the unique magnetic and kinetic properties of EVP-ABD provide high levels of enhancement for both blood vessels and liver. Additional studies have demonstrated a safety profile similar to marketed agents. These features should overcome limitations to the use of MRI for liver and provide better discrimination between various malignant and benign lesions. Such potential will be assessed in Phase II.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44DK058420-02A1
Application #
6548823
Study Section
Special Emphasis Panel (ZRG1-SSS-7 (11))
Program Officer
Podskalny, Judith M,
Project Start
2000-09-15
Project End
2004-07-31
Budget Start
2002-08-09
Budget End
2003-07-31
Support Year
2
Fiscal Year
2002
Total Cost
$490,987
Indirect Cost
Name
Eagle Vision Pharmaceutical Corporation
Department
Type
DUNS #
City
Downingtown
State
PA
Country
United States
Zip Code
19335